Theriva Biologics
TOVX
27 hedge funds and large institutions have $53M invested in Theriva Biologics in 2014 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
69% more capital invested
Capital invested by funds: $31.4M → $53M (+$21.5M)
17% more funds holding
Funds holding: 23 → 27 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.1M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$1.06M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$973K |
| 4 |
Morgan Stanley
New York
|
+$745K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$331K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$2.73M |
| 2 |
RA
Royce & Associates
New York
|
-$1.18M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$283K |
| 4 |
LOM
Loeb Offshore Management
New York
|
-$122K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$41.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GC
26
Guggenheim Capital
Chicago,
Illinois
| $42K | +$20.7K | +1 | +100% |
|
27
Stifel Financial
St. Louis,
Missouri
| $26K | +$20.7K | +1 | New |
|
|
GT
28
Glenmede Trust
Philadelphia,
Pennsylvania
| $6K | – | – | – |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $4K | – | – | – |
|
30
BNP Paribas Financial Markets
Paris,
France
| $1.6K | – | – | – |
|
31
Citigroup
New York
| $1K | – | – | – |
|
32
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
DCM
33
DAFNA Capital Management
Los Angeles,
California
| – | -$283K | -21 | Closed |
|
|
LOM
34
Loeb Offshore Management
New York
| – | -$122K | -9 | Closed |
|
35
Dimensional Fund Advisors
Austin,
Texas
| – | -$22K | -2 | Closed |
|
36
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$1 | – | – |
|
TOVX Hedge Fund Activity: Q1 2014 in Review
27 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2014, worth a combined $53M — up 69% from $31.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TOVX positions and 3 closed out — a net gain of 5 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was TFS Capital, opening a new position worth an estimated $1.1M. The largest seller was Belmont Global Advisors, cutting an estimated $2.73M.
- 27 institutional investors held Theriva Biologics (TOVX) as of Q1 2014, up from 23 in Q4 2013.
- Funds reported $53M of Theriva Biologics stock for Q1 2014, up 69% quarter-over-quarter.
- 8 funds opened new Theriva Biologics positions in Q1 2014 and 3 closed out, a net change of +5 holders.
- The largest Theriva Biologics buyer in Q1 2014 was TFS Capital, an estimated $1.1M added.
- The largest Theriva Biologics seller in Q1 2014 was Belmont Global Advisors, an estimated $2.73M sold.
Based on aggregated 13F filings for Q1 2014.